Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB264 Plus Inetetamab in HER2-Positive Breast Cancer Progressing After T-DXd
NCT07182721Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Sep 2025
- Primary completion
- Sep 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan and inetetamab in breast cancer, sponsored by Fudan University. Primary endpoint: Objective Response Rate at 52 weeks. Started Sep 2025; status: recruiting.
02
Drugs
sacituzumab tirumotecaninetetamab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07182721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07182721.